Randomized double-blind controlled study of Guanxin Danshen Dripping Pills in treatment of blood-stasis syndrome of CAD

the key techonology of Evaluate clinical effect of Chinese medicine in the treatment of blood-stasis syndrome of CAD

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-11001839

Enrollment

Unknown

Registered

2011-12-04

Start date

2011-10-24

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

blood-stasis syndrome of CAD

Interventions

1:Conventional therapy combine with Guanxin Danshen Dripping Pills

2:Conventional therapy

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. patients were selected subject to one of the following coronary heart disease diagnostic criteria: 1) Having a history of old myocardial infarction least half a year or more; 2) Underwent PCI, or coronary artery bypass least three month or more ago; 3) The results of coronary angiography suggest that at least one coronary artery diameter stenosis >=50%; 4) The results of Coronary CTA suggest that main coronary stenosis >=50%; 5) Diagnosed as coronary artery disease myocardial ischemia by myocardial nuclide imaging; 2. Patients with Acute coronary syndrome have been in stable condition for more than three months after treatment; 3. Syndrome Differentiation of TCM is Blood Stasis Syndrome (including Complex syndromes,such as Qi Deficiency and Blood Stasis Syndrome).

Exclusion criteria

Exclusion criteria: 1. having a history of AMI, Underwent PCI or CABG less than three months?classification of unstable angina is grade I, IV; 2. Having Other heart diseases, Severe cardiopulmonary dysfunction (heart function class III, IV, pulmonary function incompetence), Severe Neurosis, Menopausal syndrome; 3. Having Acute cerebrovascular disease; 4. bad-controlled hypertension (systolic blood pressure >=160mmHg and diastolic blood pressure >=100mmHg); 5. malignancy arrhythmia (such as paroxysmal ventricular tachycardia) are relapsing repeatedly recently; 6. Having other serious primary diseases of hepatic, renal and hematopoietic system, or psychosis; 7. Woman in Pregnancy, Planned pregnancy or lactation period; 8. Underwent craniocerebral, thoracic and abdominal operation in the past four weeks and having bleeding tendency; 9. participated in other clinical trials in the past a month; 10. allergic constitution or a known allergy to the study medication.

Design outcomes

Primary

Measure	Time frame
symptoms;physical sign;tongue sign;pulse sign;Blood and urine routine examination, liver function, kidney function, Blood coagulation;	—

Countries

China

Contacts

Public ContactShi Da-Zhuo

shidazhuo@126.com+86 10 62860449

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026